AlphAIAlphAI — Financial news for AI agents
Financial news API & MCP server

Financial newsfor AI agents.

Stock market news and SEC filing updates, scored for relevance and sentiment. Available through a REST API and MCP server.

Connect an agentRead the feed
Get a free API keyInsider trading tracker

Free tier available. No credit card.

10,000+
Articles scanned daily

Crawled and deduplicated across the open web.

6,900+
Sources monitored

Distinct publisher domains scanned in the last 30 days.

<1 in 5
Makes the feed

Only the best clear the relevance floor.

~6 min
SEC filing to feed

Median from EDGAR publication to an enriched, ticker-tagged row.

Top stories

All stories →
OtherOCT 269 / 10

Summit Therapeutics reports Phase III overall‑survival win for ivonescimab in advanced biliary tract cancer

Summit Therapeutics announced that its bispecific antibody ivonescimab combined with chemotherapy achieved a statistically significant overall‑survival advantage over durvalumab plus chemotherapy in the HARMONi‑GI1 Phase III trial of first‑line advanced biliary tract cancer. Median overall survival was 14.9 months versus 12.1 months, corresponding to a hazard ratio of 0.75 (25% reduction in death risk). The regimen also improved median progression‑free survival to 8.4 months versus 5.8 months and raised objective response and disease‑control rates to 53.8%/91.5% versus 32.5%/77.8%.

$SMMT6 sources · 6 publishers
Delivery

News alerts in Telegram, email, or a webhook.

Set up alerts →
On the wire
$GSKGSK's Ovarian Cancer Drug Shows Durable Responses in Early-stage Trial$BMYBristol Myers Squibb's trial drug nearly doubled time before lung cancer worsened.$CRMStocktwits M&A Watch: CRM, BRZE, TW, LEU Stocks In Focus

Latest

See all news →
OCT 26
$ESLTMedAI 8/10

Elbit Systems Secures Around $200 Mln Contracts

Elbit Systems (ESLT) announced $200 million in contracts from an Asia-Pacific country for airborne intelligence and training solutions. The deals, spanning up to 5 years, include SPECTRO 12 payloads, support services, and advanced head-up displays.

rttnews.com1 min
OCT 26
Med

SWI Compute Emerges from Stealth to Turn Gigawatts of Power Into NVIDIA AI Factories, Starting in Europe

SWI Compute, a subsidiary of Euronext Amsterdam-listed SWI Group, launched to build and operate NVIDIA AI factories, starting in Europe. The company has secured 3.6 GW of power capacity and ordered $1 billion in NVIDIA systems. Its first UK AI factory, with 30 MW capacity, is expected online by late 2027, part of a plan to reach 2.3 GW by 2029. SWI Compute aims to provide dedicated AI infrastructure for European AI natives, labs, and enterprises.

prnewswire.com2 min
OCT 26
$GSKMed

GSK: AZUR-1 Data Demonstrates Potential Of Jemperli

GSK reported positive interim results from the phase II AZUR-1 trial for Jemperli, showing 76% of patients achieved complete response. Additionally, updated data from the phase I BEHOLD-1 trial for Mo-Rez in platinum-resistant ovarian cancer showed a 62% objective response rate and 11.1 months of progression-free survival. GSK shares closed at 1,893.28 pence on the LSE.

rttnews.com1 min
OCT 26
$GSKMedAI 9/10

GSK cancer drug clears rectal tumours in 76% of patients in trial, data shows

GSK (LON:GSK) reported that its immunotherapy Jemperli cleared tumors completely in 76% of patients with a specific type of rectal cancer in a phase II trial. The trial met its main goal, with 47% of evaluable patients showing a complete response lasting 12 months. GSK also reported positive results for its experimental antibody-drug conjugate Mo-Rez in ovarian cancer, with a 62% response rate.

investing.com2 min
OCT 26
$NVSLow

Novartis AG: Gets a Neutral rating from RBC

Novartis AG received a 'Neutral' rating from both RBC and Barclays. The ratings are based on various composite factors, including valuation, EPS revisions, and visibility. Novartis' stock is currently trading at 128.00 CHF, with a 5-day change of -0.68% and a year-to-date change of +16.79%.

marketscreener.com1 min
OCT 26
$BMYMedAI 8/10

Iza-bren shows positive results in lung cancer trial

SystImmune and Bristol Myers Squibb reported that a Phase 3 trial of izalontamab brengitecan (iza-bren) met its primary endpoint in EGFR-mutated non-small cell lung cancer patients. The trial showed iza-bren achieved a median progression-free survival of 11.1 months compared to 5.7 months for chemotherapy. The drug is jointly developed by the two companies outside of China.

investing.com2 min
What people build

Built for AI agents and trading bots.

01MCP

"Claude, what moved NVDA today?"

alphai_news_search → MCP

Try it
02REST API

"Send only high-relevance earnings news for my watchlist."

/api/news/?category=earnings · min_relevance=7

Try it
03REST API

"Build a Telegram bot for market-moving news in 10 minutes."

/api/news/trending/ + your bot framework

Try it
04MCP

"Any insider buying in my watchlist this week?"

alphai_insider_news → MCP · /api/news/insider/

Try it
05MCP

"Feed my agent relevance-scored financial news via MCP."

OAuth 2.1 · News & watchlist tools · Streamable HTTP

Try it
Built for developers

Stock news API with sentiment and relevance scores

The same scored news feed that powers AlphAI is available as a REST API, and as an MCP server for Claude Desktop, Cursor, and any other agent host. Articles arrive enriched and linked to tickers in real time.

  • Real-time + historical news
  • Per-ticker filters and search
  • Relevance-scored 1–10
  • Free tier + paid scale
Stock news API documentationFinancial news MCP server

Dropping it into an existing stack? The Python and n8n quick starts are copy-paste.

GET /api/news/
curl https://api.alphai.io/api/news/ \
  -H "Authorization: Bearer ${ALPHAI_API_KEY}" \
  -G -d "symbol=NVDA"

# → {
#   "results": [{
#     "original": {
#       "title": "Nvidia export curbs tighten...",
#       "summary": "The White House is expected to...",
#       "time_published": "2026-04-18T14:32:00Z"
#     },
#     "enrichment": {
#       "category": "macro",
#       "tickers": ["NVDA"],
#       "relevance_score": 9
#     }
#   }, ...],
#   "next_cursor": "MjAyNi0wNC0xOFQxNDozMjowMHw0Mg=="
# }
Pricing

Three plans. One feed.

Free reads the feed and probes the APIs. Paid plans drop the ads and scale up the rate.

See all plans

Free

$0forever
  • Unlimited articles on the website
  • REST + MCP: 20 / min · 100 / day each, 1 API key
  • Sponsored placements visible
Start for free

Basic

Early access
$2.99$7.99/month
  • No ads, unlimited watchlist
  • Daily digest of ticker alerts
  • REST API: 60 / min · 10,000 / day, 1 key
  • MCP server: 60 / min · 10,000 / day
Get started
Most popular

Pro

Early access
$9.99$24.99/month
  • Everything in Basic
  • REST API: 150 / min · 100,000 / day, 5 keys
  • MCP server: 150 / min · 100,000 / day + bulk
Get started

Subscribe now and keep this rate for as long as you stay subscribed. We will not raise it for you.

Don’t want to watch the feed? Follow a ticker and we’ll deliver a daily digest of everything that clears your relevance bar, so you don’t have to check back.

Set up alerts